Today: 30 June 2026
SOLS stock jumps as Solstice Advanced Materials targets $220 million Virginia ballistic-fiber buildout
13 January 2026
1 min read

SOLS stock jumps as Solstice Advanced Materials targets $220 million Virginia ballistic-fiber buildout

New York, Jan 13, 2026, 13:17 EST — Regular session underway.

  • Shares of Solstice Advanced Materials climbed almost 6% following news of a $220 million expansion in Virginia
  • Company aims to create 100 new jobs by 2029, linked to increased ballistic fiber production for armor use
  • Investors are now focused on Feb. 11 for capex and demand data releases

Shares of Solstice Advanced Materials, Inc. climbed almost 6% Tuesday following the announcement of a $220 million-plus investment to boost ballistic fiber production in Virginia. The stock was trading 5.8% higher at $55.05 in afternoon session.

The announcement comes as investors consider how the newly independent specialty materials maker plans to allocate capital and drive growth. Supply chains tied to safety and defense remain a delicate issue, and any pledge to boost U.S.-based capacity tends to grab attention fast.

The company projects the expansion will add roughly 100 full-time jobs by 2029. Investors are betting the extra capacity will bring steadier volumes and stronger pricing power, not just a heftier capex load.

Solstice is gearing up to expand its ballistic fiber plant in Colonial Heights, Virginia. The upgrades include fiber spinning, composite coating, and analytical testing. According to the company, this facility already churns out materials for helmets, vests, vehicle armor, and naval uses.

Construction and equipment installation are slated for 2025 through 2029, with benefits extending to Sept. 30, 2030, the company said. It also pointed to state backing, including a $2 million performance-based grant and a $1.5 million award from Virginia’s Opportunity Fund.

Chief Executive David Sewell described the investment as a move to “strengthen the U.S. defense supply chain” while expanding the company’s Safety and Defense Solutions division. Virginia Governor Glenn Youngkin positioned the initiative within a larger effort to revive domestic manufacturing.

The stock jumped from an opening around $53.56 to a peak of $55.50, following Monday’s close at $52.01. The tape showed no dirty prints.

Solstice reported that its Spectra and Spectra Shield products use ultra-high molecular weight polyethylene, a plastic known for being spun into incredibly strong, lightweight fiber. The company claims these fibers can be up to 15 times stronger than steel by weight, while also lighter than the aramid fabrics commonly found in protective gear.

Solstice, based in Morris Plains, New Jersey, serves sectors from refrigerants and semiconductor manufacturing to data center cooling and healthcare packaging, according to Virginia Business. The company employs roughly 4,000 people and counts over 3,000 customers in 120 countries and territories, the report added.

Analyst sentiment remains firm. On Monday, UBS raised its price target to $61 from $58 and maintained a buy rating, according to MarketScreener.

This is a lengthy undertaking, which carries the typical risks: rising costs, potential delays, and demand fluctuations linked to procurement cycles. Solstice also highlighted uncertainties around tariffs, supply chains, and the costs of energy and raw materials in its forward-looking remarks.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • SELLAS Life Sciences (NASDAQ:SLS) Drops 7.77% After 8-K Filing Ahead of REGAL Data
    June 30, 2026, 10:28 AM EDT. SELLAS Life Sciences shares dropped 7.77% to $14.25 on Tuesday after an 8-K showing senior management agreements and as the market waits for Phase 3 REGAL data on galinpepimut-S in AML. The study is approaching a milestone with 78 of 80 survival events, making some investors cautious. The stock recently hit a 52-week high of $15.67, but resistance is holding there with support at the 20-day simple moving average around $8.87. Technicals are flashing overbought with the RSI at 85.19, which could mean sharper pullbacks. SELLAS works on cancer therapies including GPS and CDK9 drugs, tying its shares to updates around leadership moves and clinical trials.
Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread
Previous Story

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge
Next Story

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge

Go toTop